{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.Clinicalstudies.in/SOP-for-Follow-Up-and-Closure-of-Monitoring-Findings”
},
“headline”: “SOP for Follow-Up and Closure of Monitoring Findings”,
“description”: “This SOP defines procedures for the follow-up and closure of monitoring findings in clinical trials, ensuring timely CAPA implementation, documentation, and compliance with FDA, EMA, CDSCO, WHO, and ICH GCP requirements.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-26”,
“dateModified”: “2025-08-26”
}
Published on 24/12/2025
Standard Operating Procedure for Follow-Up and Closure of Monitoring Findings
| Department | Clinical Operations / Monitoring |
| SOP No. | CR/OPS/068/2025 |
| Supersedes | NA |
| Page No. | 1 of 30 |
| Issue Date | 26/08/2025 |
| Effective Date | 01/09/2025 |
| Review Date | 01/09/2026 |
Purpose
The purpose of this SOP is to describe the standardized process for follow-up and closure of monitoring findings identified during clinical trial monitoring
Scope
This SOP applies to CRAs, investigators, sponsors, CROs, study coordinators, and QA officers responsible for monitoring follow-up and CAPA management. It covers findings from onsite, remote, and central monitoring activities, including deviations, informed consent deficiencies, drug accountability issues, data entry delays, and protocol compliance concerns.
Responsibilities
- CRA/Monitor: Tracks findings, ensures CAPA is implemented, and documents closure.
- PI: Implements corrective actions at site level and provides CAPA responses.
- Study Coordinator: Assists PI in executing corrective measures and submitting evidence.
- Clinical Operations Manager: Oversees CAPA timelines and verifies resolution adequacy.
- Sponsor/CRO: Ensures follow-up findings are closed and reported per regulatory timelines.
- QA Officer: Reviews closed findings, verifies CAPA documentation, and audits process for compliance.
Accountability
The sponsor is accountable for ensuring all monitoring findings are addressed and closed. The CRA is accountable for documenting follow-up, while the PI is accountable for implementing corrective actions at site level.
Procedure
1. Identification of Findings
Document findings in Monitoring Visit Report (MVR).
Categorize findings as Critical, Major, or Minor.
Share findings with site PI within 10 working days.
2. CAPA Development
PI/site staff develop CAPA plan for each finding within 15 working days.
CAPA plan must address root cause, corrective action, and preventive action.
Submit CAPA plan to CRA and sponsor for review.
3. CAPA Implementation
Site executes corrective actions (e.g., retraining staff, updating records, revising procedures).
CRA verifies implementation during follow-up visit or remote review.
Record updates in CAPA Log (Annexure-1).
4. Documentation of Evidence
PI provides evidence of corrective actions (signed logs, updated consent forms, reconciliation reports).
CRA ensures all evidence is filed in TMF/ISF.
5. Closure Verification
CRA confirms CAPA effectiveness and documents closure in Finding Closure Log (Annexure-2).
Clinical Operations Manager approves closure.
QA performs independent review for selected findings.
6. Timelines
CAPA submission: within 15 working days of receiving MVR.
CRA follow-up verification: within 30 working days.
Closure approval: within 45 working days.
7. Escalation
If CAPA is not implemented or ineffective, escalate to sponsor immediately.
Document in Escalation Log (Annexure-3).
8. Archiving
Archive CAPA logs, closure documentation, and escalation records in TMF.
Retain for at least 15 years or per local regulations.
Abbreviations
- SOP: Standard Operating Procedure
- PI: Principal Investigator
- CRA: Clinical Research Associate
- CRO: Clinical Research Organization
- QA: Quality Assurance
- TMF: Trial Master File
- ISF: Investigator Site File
- CAPA: Corrective and Preventive Action
- MVR: Monitoring Visit Report
Documents
- CAPA Log (Annexure-1)
- Finding Closure Log (Annexure-2)
- Escalation Log (Annexure-3)
References
- ICH E6(R2) – Good Clinical Practice
- FDA – Guidance on Risk-Based Monitoring
- EMA – Monitoring and CAPA Management
- CDSCO – Monitoring and CAPA Requirements
- WHO – Monitoring Follow-Up Guidance
Version: 1.0
Approval Section
| Prepared By | Ravi Kumar, CRA |
| Checked By | Sunita Reddy, QA Officer |
| Approved By | Dr. Anil Sharma, Principal Investigator |
Annexures
Annexure-1: CAPA Log
| Date | Finding | CAPA | Responsible | Status |
|---|---|---|---|---|
| 12/09/2025 | Incomplete IP accountability | Training + reconciliation | PI | Open |
| 14/09/2025 | Delayed CRF entry | Staff retrained | Coordinator | Closed |
Annexure-2: Finding Closure Log
| Date | Finding | Closure Evidence | Verified By | Status |
|---|---|---|---|---|
| 15/09/2025 | Consent form incomplete | Corrected and filed | CRA | Closed |
| 16/09/2025 | SAE not reported on time | Retraining completed | CRA | Closed |
Annexure-3: Escalation Log
| Date | Issue | Escalated To | Resolution | Closed By |
|---|---|---|---|---|
| 17/09/2025 | Repeated late SAE reporting | Sponsor | CAPA reinforced | QA Officer |
| 18/09/2025 | Persistent drug accountability errors | Clinical Ops Manager | Site retrained | Sponsor |
Revision History
| Revision Date | Revision No. | Revision Details | Reason for Revision | Approved By |
|---|---|---|---|---|
| 26/08/2025 | 00 | Initial version | New SOP creation | Head, Clinical Operations |
For more SOPs visit: Pharma SOP